SCHEMBL721627

SCHEMBL721627

Cc1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4C)c3o2)cc1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 3/20 0.40
PRKCQ Q04759 15/20 0.37
PRKCD Q05655 15/20 0.37
LYN P07948 4/20 0.36
KDR P35968 1/20 0.34
ADRA2A P08913 1/20 0.33
ADRA2C P18825 1/20 0.33
PRKCB P05771 1/20 0.33
LCK P06239 1/20 0.33
PRKCH P24723 1/20 0.33
PRKCE Q02156 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723489 0.92 PRKCQ (0.37) MAPKAPK2PRKCQPRKCDLYNADRA2A
SCHEMBL723524 0.92 PRKCQ (0.44) PRKCQPRKCDLYNKDRPRKCB
SCHEMBL726781 0.90 PRKCQ (0.34) MAPKAPK2PRKCQPRKCDLYNPRKCB
SCHEMBL10267539 0.90 PRKCQ (0.47) PRKCQPRKCDLYNKDRADRA2A
SCHEMBL721326 0.89 PRKCQ (0.41) PRKCQPRKCDLYNPRKCBLCK
SCHEMBL723399 0.89 PRKCQ (0.40) MAPKAPK2PRKCQPRKCDLYNKDR
SCHEMBL725010 0.86 PRKCQ (0.50) PRKCQPRKCDLYNLCK
SCHEMBL724640 0.86 JAK2 (0.44) MAPKAPK2PRKCQPRKCD
SCHEMBL721499 0.86 PRKCQ (0.43) PRKCQPRKCDLYNADRA2AADRA2C
SCHEMBL722230 0.86 ADRA2A (0.39) PRKCQPRKCDLYNKDRADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
CN-103052640-A Furopyridine derivatives MERCK PATENT GMBH 2013-04-17 CN claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB MAPKAPK2 867/4885PRKCQ 662/4885PRKCD 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.